Last reviewed: June 20, 2026
Last updated: June 20, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Both semaglutide and tirzepatide activate GLP-1 receptors to reduce hunger and improve metabolic control, yet tirzepatide adds a second mechanism by also targeting GIP receptors, creating a dual-action effect that clinical trials have shown produces greater average weight loss. Choosing between these medications depends on individual metabolic response, genetic predisposition, and treatment goals. PlexusDx offers compounded versions of both medications, allowing patients to find the right fit for their body without membership fees or insurance requirements.
How Semaglutide and Tirzepatide Differ in Mechanism
Semaglutide functions as a GLP-1 receptor agonist, signaling to appetite centers in the brain and slowing stomach emptying to create sustained fullness. This single-pathway approach has been studied extensively over nearly a decade and remains the foundation of modern weight loss therapy. Patients using semaglutide typically experience gradual, predictable weight reduction and improved blood sugar control.
Tirzepatide activates both GLP-1 and GIP receptors—a dual increttin approach that addresses hunger through multiple biological channels. The GIP pathway targets fat storage regulation and energy expenditure in addition to appetite suppression. This two-receptor strategy explains why tirzepatide demonstrated approximately 22% body weight reduction in clinical trials, compared to roughly 15% with semaglutide at comparable dosing phases.
Clinical Trial Data: Weight Loss Outcomes and Safety
The SURMOUNT trial series documented tirzepatide's efficacy across three randomized controlled studies involving over 5,000 participants. Participants on the highest tirzepatide doses achieved mean weight losses exceeding 20% of baseline body weight over 68 weeks, with sustained reductions maintained at one-year follow-up. Gastrointestinal side effects, primarily nausea and vomiting, occurred in roughly 25-33% of participants but typically resolved within the first month of therapy.
Semaglutide's safety and efficacy profile comes from the STEP trial program, which followed similar methodologies across multiple cohorts. Weight loss ranged from 10% to 18% depending on final dose, with nausea affecting approximately 20-25% of users, usually as a transient symptom. Both medications show comparable improvements in cardiovascular outcomes and blood pressure reduction, though long-term cardiovascular benefit data for tirzepatide continues to accumulate.
Personalized Treatment Selection Using Genetic Insights
Individual genetic variation significantly influences how patients respond to GLP-1 and GIP signaling. Specific genetic variants in GLP1R (such as rs6923761) and GIPR (such as rs1800437) correlate with differential medication response and side effect tolerance. PlexusDx offers the Precision Peptide Genetic Test, which maps 14 metabolic pathways and 49 peptide-related genes to identify which medication class aligns best with a patient's genetic architecture.
The FTO and MC4R variants further refine treatment selection by revealing appetite regulation patterns and energy expenditure capacity. Patients with certain FTO rs9939609 alleles may show enhanced response to dual-pathway medications like tirzepatide, while others achieve optimal results with monotherapy. This genetic roadmap transforms weight loss therapy from trial-and-error to precision medicine, reducing time to therapeutic response and improving adherence by matching drug to biology rather than guessing.
Availability, Pricing, and Access at PlexusDx
PlexusDx compounded tirzepatide injection begins at $249 per month with flat pricing across commitment tiers—meaning your dose may increase during therapy, but your monthly cost remains stable. All medications source from licensed 503A compounding pharmacies and reach all 50 states without insurance requirements, membership fees, or referral barriers. Patients can use HSA or FSA funds, making precision therapy accessible regardless of employment status or insurance coverage.
For those exploring dual-compound therapy, the GLP-Squared injection combines semaglutide and tirzepatide in one formulation, starting at $249 monthly. Alternatively, semaglutide injection alone costs $149 monthly, and oral versions of both medications offer flexibility for needle-averse patients. After your first month of treatment, adding the Precision Peptide Genetic Test ($99 one-time) optimizes long-term medication selection and dose progression based on your individual genetic profile.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Which medication causes more side effects—semaglutide or tirzepatide?
Both medications produce similar side effect profiles, with nausea affecting 20-33% of users during the first month. Tirzepatide users report slightly higher rates of gastrointestinal symptoms, though most resolve within 4-6 weeks. PlexusDx's slow-escalation dosing protocols and genetic testing help identify patients likely to tolerate each medication better before starting therapy.
How much weight can I expect to lose with tirzepatide versus semaglutide?
Clinical trials show tirzepatide produces approximately 22% body weight reduction compared to 15% with semaglutide at equivalent dose phases. However, individual results vary significantly based on genetics, lifestyle, and adherence. PlexusDx patients using the Precision Peptide Genetic Test receive personalized projections based on their GLP1R, GIPR, and FTO genotypes.
Can I switch from semaglutide to tirzepatide if my results plateau?
Yes, switching between medications is medically feasible and often recommended when weight loss stalls. PlexusDx supports medication transitions without increasing your monthly cost, and the Precision Peptide Genetic Test can guide whether tirzepatide's dual-pathway approach better matches your metabolic genetics than semaglutide monotherapy.
Is tirzepatide at $249/month the lowest price for this medication?
PlexusDx's tirzepatide injection pricing starts at $249 monthly with flat rates across all commitment tiers, ensuring predictable costs regardless of dose level. This eliminates hidden increases as your therapy progresses. HSA/FSA eligibility further reduces out-of-pocket expenses, and no insurance, membership, or referral is required.
What does the Precision Peptide Genetic Test reveal about my medication response?
The test analyzes 49 peptide-related genes across 14 metabolic pathways, including key variants like GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These insights predict your likely response to semaglutide versus tirzepatide, optimal dose escalation speed, and risk of side effects—transforming your therapy from generic to personalized from month one.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Much Weight Do You Gain After Stopping Wegovy?
Navigating Your Journey: How Does a Wegovy Pen Work for Effective Weight Loss?